More Videos
SPECIAL REPORT
MOST SHARED
- BlackRock: Central Banks To Be Net Buyers of Gold
- Cisco Ups Tandberg Bid, Claims Over 40% Backing
- Millions May Have to Repay Part of Obama Tax Credit
- Gold Is in a 'Bubble' And Will Keep Going Higher: Gartman
- Weak US Housing Market Drags on Lowe's Profit
- Underwater Mortgages Could Sink Even Deeper
- Madoff Auction: $4,750 for a Decoy Duck?
- Devon to Sell its Gulf, International Assets
- U.S. May Wind Up Green With Envy
- Will the S&P 500 Close Above 1100?
- What Were The Northwest Pilots Really Doing?
- Your Jobless Recovery Game Plan
- S&P to Hit 1,175 in the Short Term: Strategist
- Busch: US Health Care Bill a Concern for the Chinese
- Underwater Mortgages Could Sink Even Deeper
- My Market and Fed Outlook Now: BlackRock's Doll
- Farrell: The Market is Still Seeking Reassurance
- GM Cuts Losses—Plans Early Loan Repayment
- Millions Could Have to Repay Part of Obama's Tax Credit
- What Recovery? Many Homeowners Still Underwater
- Gold Is in a 'Bubble' And Will Keep Going Higher: Gartman
- Madoff Auction: $4,750 for a Decoy Duck?
- Slideshow: Madoff's Luxury Boats Go Up for Auction
- Retail Sales Show Gain, But Manufacturing Gauge Slips
- How Much Do You Know About Green?
- Solar Energy Emerges From a Dark Period
- Drillers Seek Scotch Lost in Antarctica in 1909
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
 |
In my mail slot this morning I found a complimentary copy of a new version of the "Merck Manual."
Thanks, Merck[MRK
Loading...
()
].
It'll be put to good use here in the CNBC newsroom where co-workers seem to think that just because my producer and I cover pharma that we're able to diagnose their or their loved ones' ailments, recommend the right drug and get them free samples.
Needless to say, but I'll say it anyway, we don't do any of that. This edition is called, "The Merck Manual of Patient Symptoms" and unlike the popular, thick hardcover one that's been published across three centuries, this new one comes in a handy-dandy paperback.
As the press release that came with it says, "Compact enough to carry in a lab coat pocket, the paperback helps health care practitioners, particularly those who are newcomers to clinical diagnosis, understand and evaluate a wide range of symptoms."
Excuse me? I don't know about you, but I don't think I want to see a nurse practitioner, physician assistant or med student at a teaching hospital whip out a "Merck Manual" to figure out what's wrong with me. Can you say, "I want a second opinion"?
Meantime, investors are trying to figure out what's ailing Merck. The stock hit another new intra-day low this morning of around 30-and-a-half bucks. MRK is one of a handful of Dow components not participating in today's rally--at least, not yet. (Pfizer[PFE
Loading...
()
], by the way, is up significantly for the second straight day).
What could be pressuring MRK is a bearish call by Steve Scala at Cowen and Company. This morning he put out a research note to clients cutting his earnings estimates from this year all the way through 2015. Scala still has an "Outperform" rating on MRK, but he's reducing sales estimates for the HPV/cervical cancer vaccine Gardasil and the allergy/asthma drug Singulair. And he thinks MRK will have to lower its earnings guidance soon because of that. On the plus side, Scala--like many other analysts--points to the nearly five percent dividend yield.
Scala owns MRK stock. He's long, not short.
Now, if only Merck had a manual on how to fix the economy, credit crisis and financial markets.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes